166 related articles for article (PubMed ID: 26416046)
1. Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.
Triantafyllidou O; Vlachos IS; Apostolou P; Konstantopoulou I; Grivas A; Panopoulos C; Dimitrakakis C; Kassanos D; Loghis C; Bramis I; Vlahos N; Yannoukakos D; Fostira F
J BUON; 2015; 20(4):978-84. PubMed ID: 26416046
[TBL] [Abstract][Full Text] [Related]
2. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
[TBL] [Abstract][Full Text] [Related]
4. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Hartman AR; Kaldate RR; Sailer LM; Painter L; Grier CE; Endsley RR; Griffin M; Hamilton SA; Frye CA; Silberman MA; Wenstrup RJ; Sandbach JF
Cancer; 2012 Jun; 118(11):2787-95. PubMed ID: 22614657
[TBL] [Abstract][Full Text] [Related]
7. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
8. Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
Kolben T; Hary T; Holdt LM; Schwarz TM; Goess C; Wuerstlein R; Gallwas J; Toth B; Weissenbacher T; Jeschke U; Harbeck N; Ditsch N
Anticancer Res; 2016 Jun; 36(6):3185-90. PubMed ID: 27272846
[TBL] [Abstract][Full Text] [Related]
9. Proven non-carriers in BRCA families have an earlier age of onset of breast cancer.
Vos JR; de Bock GH; Teixeira N; van der Kolk DM; Jansen L; Mourits MJ; Oosterwijk JC
Eur J Cancer; 2013 Jun; 49(9):2101-6. PubMed ID: 23490645
[TBL] [Abstract][Full Text] [Related]
10. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
11. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
[TBL] [Abstract][Full Text] [Related]
12. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
[TBL] [Abstract][Full Text] [Related]
13. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?
Panchal S; Bordeleau L; Poll A; Llacuachaqui M; Shachar O; Ainsworth P; Armel S; Eisen A; Sun P; Narod SA
Clin Genet; 2010 Mar; 77(3):273-9. PubMed ID: 20002453
[TBL] [Abstract][Full Text] [Related]
14. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
[TBL] [Abstract][Full Text] [Related]
15. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
Bonadona V; Dussart-Moser S; Voirin N; Sinilnikova OM; Mignotte H; Mathevet P; Brémond A; Treilleux I; Martin A; Romestaing P; Raudrant D; Rudigoz RC; Lenoir GM; Lasset C
Breast Cancer Res Treat; 2007 Jan; 101(2):233-45. PubMed ID: 17061047
[TBL] [Abstract][Full Text] [Related]
17. Dissimilarity between sporadic, non-BRCA1/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population.
Riahi A; Gourabi ME; Chabouni-Bouhamed H
Breast Cancer; 2016 Sep; 23(5):807-12. PubMed ID: 26476744
[TBL] [Abstract][Full Text] [Related]
18. Diet quality and BRCA-associated breast cancer risk.
Nkondjock A; Ghadirian P
Breast Cancer Res Treat; 2007 Jul; 103(3):361-9. PubMed ID: 17063275
[TBL] [Abstract][Full Text] [Related]
19. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
20. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]